<--- Back to Details
First PageDocument Content
Pharmaceutical sciences / Clinical pharmacology / Pharmacology / Therapeutics / United States Public Health Service / Center for Drug Evaluation and Research / Wake Forest School of Medicine / Nicholas J. Vogelzang / Andrew von Eschenbach / Medicine / Health / Food and Drug Administration
Pharmaceutical sciences
Clinical pharmacology
Pharmacology
Therapeutics
United States Public Health Service
Center for Drug Evaluation and Research
Wake Forest School of Medicine
Nicholas J. Vogelzang
Andrew von Eschenbach
Medicine
Health
Food and Drug Administration

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 77,61 KB

Share Document on Facebook

Similar Documents

April 16, 2018 American Herbal Pharmacopoeia® and Therapeutic Compendium Standards of Analysis, Quality Control, and Therapeutics AHP Releases Monograph Standards, Motherwort Aerial Parts (Leonurus cardiaca; Leonurus qu

DocID: 1voig - View Document

Initiating Coverage December 18, 2014 InVivo Therapeutics (NVIV) Initiation Report

DocID: 1vapl - View Document

  Warp Drive Bio Appoints Steven H. Holtzman to its Board of Directors CAMBRIDGE, Mass., October 17, 2016 – Warp Drive Bio, a life sciences company developing therapeutics that exploit the molecules and mechanisms of

DocID: 1v3IN - View Document

Warp Drive Bio to Present at Cowen and Company 38th Annual Health Care Conference CAMBRIDGE, Mass., March 13, Warp Drive Bio, Inc., a drug discovery company developing therapeutics that exploit the molecules and

DocID: 1v3kf - View Document

Terms of Use Welcome to www.daytrana.com, a website owned by Noven Pharmaceuticals, Inc. This website is produced by Noven Therapeutics LLC. The information provided on this site is for general information and educationa

DocID: 1v0Hj - View Document